| 2024-10-01 | -2.36 % |
|
| 2024-09-26 | +1.95 % |
|
| 2024-09-25 | -3.28 % |
|
| 2024-09-24 | -0.48 % |
|
| 2024-09-20 | -1.02 % |
|
| 2024-09-17 | +0.25 % |
|
| 2024-09-04 | +0.01 % |
|
| 2024-09-03 | -1.09 % |
|
| 2024-08-14 | -0.94 % |
|
| 2024-08-05 | -3.36 % |
|
| 2024-08-01 | +0.87 % |
|
| 2024-07-25 | -2.71 % |
|
| 2024-07-24 | -0.02 % |
|
| 2024-07-23 | -2.63 % |
- IQVIA Holdings (NYSE:IQV) stock declined by 2.63% following a mixed financial outlook update from Truist Securities, which, despite raising its price target and adjusted EPS estimates, also lowered its revenue forecasts for Research & Development Solutions.
- IQVIA's stock (IQV) fell by 2.63% after the company reported a modest 2.3% revenue increase in the second quarter of 2024, despite strong performance and growth projections, which may signal investor concern about the company's cautious growth relative to broader expectations or market conditions.
- IQVIA Holdings (NYSE:IQV) stock fell by 2.63% despite Deutsche Bank maintaining a Buy rating and a price target of $275, amidst ongoing investor skepticism regarding projected growth in Technology & Analytics Solutions (TAS) and concerns over client budget constraints and project delays.
- IQVIA Holdings Inc (NYSE:IQV) stock fell by 2.63% despite showcasing strong revenue growth and earnings, which may be attributed to industry-specific risks, regulatory challenges, rising operational costs, and competitive pressures outlined in the recent analysis.
|
| 2024-07-22 | +9.2 % |
|
| 2024-07-19 | -0.12 % |
|
| 2024-07-15 | +0.77 % |
|
| 2024-07-12 | +2.16 % |
|
| 2024-07-11 | +3.52 % |
|
| 2024-07-01 | -1.4 % |
|
| 2024-06-27 | +0.74 % |
|
| 2024-06-26 | -0.11 % |
|
| 2024-06-24 | -1 % |
- The article discusses the upcoming 2024 Fierce Clinical Summit organized by Fierce Pharma, which will cover various topics related to clinical research and trial management, with major sponsors being IQVIA, Advarra, and H1; the reason why IQVIA (IQV) stock was down by -1.0% could be due to various factors such as market conditions, investor sentiment, company performance, or external economic events.
- The article discusses the recent -1.0% drop in IQVIA (IQV) stock and attributes it to the underperformance and lack of investor interest in two newly launched weight-loss exchange-traded funds (ETFs), Roundhill GLP-1 & Weight Loss ETF (OZEM) and Amplify Weight Loss Drug & Treatment ETF (THNR), due to their high expense ratios, concentrated exposure to Eli Lilly (LLY) and Novo Nordisk (NVO), as well as the availability of numerous other weight loss treatment assets in the market.
|
| 2024-06-21 | +0.96 % |
|
| 2024-06-18 | -0.23 % |
|
| 2024-06-14 | -0.57 % |
|
| 2024-06-12 | +0.76 % |
|
| 2024-06-11 | -0.15 % |
|
| 2024-06-10 | -1.55 % |
|
| 2024-06-07 | -0.57 % |
|
| 2024-06-06 | +0.73 % |
|
| 2024-06-05 | +0.79 % |
|
| 2024-06-03 | -1.2 % |
|
| 2024-05-31 | -1.51 % |
- The article discusses Aurobindo Pharma's USFDA approval for Mometasone Furoate Monohydrate Nasal Spray, projected to have a market size of $44.5 million, as per IQVIA data, and the company's overall operations. The decline in IQV stock price could be attributed to various factors, such as market fluctuations, investor sentiment, industry news, or company-specific events.
- The article discusses Veeva Systems Inc.'s fiscal 2025 first-quarter results, highlighting a total revenue of $650 million, non-GAAP operating income of $261 million, and a downward revision of full-year revenue guidance by $30 million to $2.71 billion due to a challenging macroeconomic environment. Veeva's resilience amidst challenges, strong fundamentals such as a significant market capitalization and gross profit margin, and strategic focus on AI applications are emphasized. The company's stock, Veeva (VEEV), generally trades with low price volatility, indicating investor confidence and a potentially lower risk profile. Despite strong performance, Veeva adjusted its revenue outlook, prompting the stock to fall by -1.51% last night, likely influenced by the revised guidance and broader market conditions.
|
| 2024-05-29 | -0.75 % |
|
| 2024-05-24 | +1.11 % |
|
| 2024-05-21 | -0.31 % |
|
| 2024-05-16 | +0.56 % |
|
| 2024-05-15 | +1.1 % |
|
| 2024-05-14 | +0.92 % |
- The article discusses Cipla Limited's Q4 FY '24 Earnings Conference Call where they reported their highest ever revenue and EBITDA, highlighting growth in various business segments and their financial performance, which led to a 0.92% increase in IQVIA (IQV) stock due to Cipla's market-leading growth in focus markets, investments in R&D, successful product launches, strong financials, and strategic partnerships.
- The article highlights that IQVIA (IQV) stock was up by 0.92% last night due to an increase in overall spending in the U.S. market for medicines, reaching $435 billion in 2023, with growth driven by areas such as oncology, immunology, diabetes, and obesity, offsetting the decline in COVID-19 vaccines and therapeutics.
|
| 2024-05-13 | -2.15 % |
|
| 2024-05-10 | +2.13 % |
|
| 2024-05-09 | +0.58 % |
|
| 2024-05-08 | -0.55 % |
- The article discusses Teva Pharmaceuticals and Medincell's announcement of positive results from the Phase 3 Subcutaneous OLAnzapine extended-Release Injection Study (SOLARIS) trial evaluating TEV-749 for schizophrenia treatment, meeting primary endpoints with statistically significant results. However, the article does not mention why IQVIA (IQV) stock went down by -0.55% last night, as it primarily focuses on the study results and potential treatment options for schizophrenia.
- Summary: Teva Pharmaceuticals and Medincell have announced positive results from the Phase 3 SOLARIS trial for the TEV-'749 drug in treating schizophrenia, showing statistically significant reductions in symptom severity compared to placebo, potentially providing an effective long-acting treatment option for schizophrenia patients.
Reason for IQV Stock Decline: The decline in IQV stock could be due to various factors such as overall market sentiment, industry trends, company-specific news, or broader economic conditions. It is essential to review the company's financial performance, analyst ratings, and market dynamics for a comprehensive understanding of why the stock decreased by -0.55%.
|
| 2024-05-06 | +1.64 % |
|
| 2024-05-02 | -4.64 % |
- Summary: The stock market saw various fluctuations in different companies' shares on May 2, 2024, with IQVIA (IQV) stock specifically down by -4.64%. The decline in stock price could potentially be due to the broader market conditions, company-specific news, economic indicators, or investor sentiment.
Reason for IQV Stock Decline: The article does not explicitly mention the reason behind IQVIA (IQV) stock going down by -4.64% on that specific day. Stock prices can be influenced by various factors such as company performance, market trends, economic conditions, analyst reports, news related to the company, or geopolitical events. Without specific information provided in the article, it is challenging to pinpoint the precise reason for the decline in IQVIA (IQV) stock.
- The article summarizes that IQVIA Holdings, a contract research firm, reduced its annual revenue forecast due to a stronger dollar and a decline in a crucial metric, leading to a nearly 4% decrease in its stock. The company cited the impact of a strengthening dollar on international sales and sluggish demand among biotech clients as reasons for the lowered forecast and decline in shares.
|
| 2024-05-01 | +0.5 % |
|
| 2024-04-30 | -1.58 % |
- The article discusses the combined management report for IQVIA (IQV) focusing on the company's restructuring to solely operate in the pharmaceutical segment, particularly in Specialty Pharma in Germany and Europe, and the impact of the global economic slowdown on the industry, with IQVIA's sales decreasing due to price increases in purchasing for a cancer drug introduced in 2022, leading to a -1.58% decline in the stock.
- The article discusses IQVIA (IQV) stock, which decreased by -1.58% last night, and provides insights into the company's recent earnings data, insider transactions, stock price, analyst ratings, and upcoming events such as the earnings release scheduled for Thursday, May 2nd. IQVIA's stock may have gone down due to insider selling and analyst downgrades.
|
| 2024-04-29 | +0.26 % |
|
| 2024-04-26 | +0.38 % |
|
| 2024-04-25 | -2.85 % |
- The article discusses how Cigna plans to offer biosimilar versions of AbbVie's arthritis drug Humira at no out-of-pocket cost to eligible patients in the U.S., leading to a potential 85% lower price compared to Humira, which has caused concerns about its impact on the market share and sales of companies like IQVIA, ultimately resulting in the -2.85% dip in the IQV stock.
- Summary: The article discusses Cegedim's solid growth in the first quarter of 2024 and revenue details, including various divisional performances. It also mentions a lawsuit involving Cegedim and IQVIA for unfair competition. IQVIA (formerly IMS Health) stock went down by -2.85% last night.
Reason for IQV stock going down: The decrease in IQVIA (IQV) stock price could be influenced by factors such as market sentiment, overall market conditions, company-specific news or developments, industry trends, or potential negative impact from the ongoing lawsuit involving Cegedim and IQVIA for unfair competition, as discussed in the article.
- The article discusses Cigna's plan to provide biosimilar versions of AbbVie's Humira drug at no out-of-pocket cost in the U.S. through its pharmacy, leading to IQVIA (IQV) stock falling by -2.85% as this move may impact Humira's market share and sales figures, causing investors to react negatively to the news.
|
| 2024-04-24 | +0.93 % |
|
| 2024-04-22 | +1.42 % |
- The article discusses EFG Asset Management Americas Corp. trimming its holdings in IQVIA Holdings Inc. (NYSE:IQV), with the stock increasing by 1.42% last night; the stock likely went up due to positive investor sentiment stemming from institutional investors increasing their positions in the company and positive earnings results, which beat analyst estimates, reported by IQVIA.
- The article discusses Zydus Lifesciences launching a generic version of the bladder control drug Mirabegron in the US, resulting in their stock rising over 3%, and IQVIA (IQV) stock going up by 1.42% last night; the boost in IQVIA stock could be attributed to the potential opportunity for the company, as it is among the first suppliers of the generic drug, making them eligible for 180 days of shared generic drug exclusivity for Mirabegron, which had an annual sale of $2.42 billion in the US market.
- The article discusses the top performing biotech ETFs in 2024 and highlights the resurgence of interest in the biotech sector driven by improved stock market performance, increased healthcare demands, emphasis on personalized medicine, and innovative therapies. IQVIA (IQV) stock went up likely due to the promising growth opportunities within the biotech sector, fueled by factors such as increasing healthcare demands, emphasis on personalized medicine, and innovative therapies.
|
| 2024-04-19 | +0.4 % |
|
| 2024-04-16 | -0.87 % |
|
| 2024-04-15 | -1.31 % |
|
| 2024-04-10 | -2.41 % |
|
| 2024-04-09 | +1.59 % |
|
| 2024-04-08 | +0.02 % |
- The article discusses Lupin Limited receiving FDA approval for its generic Valbenazine Capsules, leading to a 0.02% increase in IQVIA (IQV) stock. IQVIA's stock likely rose due to Lupin's announcement of being one of the first ANDA applicants eligible for 180 days of shared generic exclusivity, potentially impacting IQVIA's market and sales performance positively.
- The article provides updates related to the stock market on April 8, 2024, mentioning various companies, acquisitions, share prices, and market movements, with specific mention that the IQVIA (IQV) stock was up by 0.02%, attributed to optimism in global markets, foreign fund inflows, sectorial tailwinds, and expectations of Q4 earnings growth.
- IQVIA Holdings Inc. (IQV) stock was slightly up by 0.02% last night, with a 23% increase over the last year and a 71% rise over the past five years. The stock's performance has been driven by a compound earnings per share growth of 42% per year, which exceeded the average annual share price increase of 11%, indicating a more cautious market sentiment towards the stock. The recent increase in share price could be attributed to the company's improved profits over the years, suggesting potential long-term growth, despite being below the market average return.
|
| 2024-04-05 | +1.22 % |
|
| 2024-04-04 | -1.83 % |
- The article discusses how Boehringer Ingelheim plans to lay off part of its salesforce due to poor U.S. sales of its biosimilar version of AbbVie’s Humira, which has resulted in IQVIA's (IQV) stock going down by -1.83%.
- The article discusses various updates in the healthcare technology industry, including ventures involving AI and automation, as well as developments in companies like Epic, Manifold, SnapCare, and Cerberus Capital Management. The reason for the -1.83% decrease in IQVIA (IQV) stock price is not directly mentioned in the article, but it could potentially be due to market fluctuations, investor sentiment, or industry-specific factors impacting the healthcare technology sector.
- The article discusses Simulations Plus, Inc.'s strong revenue growth and positive outlook for its products and services, highlighting its focus on strategic expansion and operational efficiency. Despite some market uncertainties, the company remains optimistic about its performance and growth potential. The reason for IQV stock going down is not explicitly mentioned in the article as it primarily focuses on Simulations Plus, Inc.'s financial results and outlook.
|
| 2024-04-03 | -1.03 % |
|
